defin pnh landscap
beat rais quartersinvestor remain acut focus
ultomiri inde increas competit concern ip worri weigh
stock ytd even top- bottom-lin
growth expans mid- late-stag pipelin three recent deal
readi new soliri product cycl ou gmg nmo see alexion
pharmaceut nmo add growth lever pt ahead
meet dec san diego spoke kol get updat view
complement competit landscap view addit phase pnh
data upcom phase ahu result expect overal continu
bullish share base sentiment improv upsid
project robust transit soliri given strong demand
improv dose schedul support high expect posit
clinic data real-world outcom minim near-term competit threat
inde modestli consensu total revenu
significantli ahead sale increas clariti alexion
next leg growth stock remain top pick ow rate pt
kol takeaway soliri high administr burden major caus
discontinu ahu phase trial expect posit initi adopt
ahu like slow prescrib convinc sustain efficaci abil
treat flare-up patient eventu like switch
requir soliri week dose initi switch like driven patient
alexion competit threat consid minim new entrant like vie
model impact result model chang continu forecast
non-gaap ep updat npv contribut
soliri
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
growth soliri pnh/ahu growth driven
sale refractori gmg assum
approv extend dose option
pnh ahu support long-term
viabil complement franchis recent fx
improv
greater expect growth soliri current
indic ahu pnh gmg label
expans soliri nmo posit data
rapid uptak iv
subcutan formul support upsid case
biosimilar competit soliri
time frame high price pressur ww
geographi addit failur
pnh ahu increas fx headwind
macroeconom issu support downsid case
follow recent disclosur pnh phase data well discuss
kol updat model see thought
complement relat abstract posit data set next
leg alexion stori specif model launch
pnh us ou po ahu us ou po
modest first uptak account initi prescrib inertia acceler
third fourth year post launch assum modest price discount
rel soliri us ou yet model gmg phase iv
formul initi nmosd soliri file result slightli
consensu figur
price target composit chang result model larg unchang
figur howev updat price target composit price target
base sum-of-th part npv analysi forecast sale soliri
strensiq kanuma includ termin valu use
discount rate vs prior soliri strensiq forecast period
think appropri reflect risk portfolio termin valu assum
less growth rate discount rate deriv valu
soliri vs prior vs prior share
strensiq vs prior kanuma combin net cash
vs prior result total npv share
soliri high administr burden major caus
discontinu unmet need
kol unequivoc assess soliri game-
changer treatment rare diseasesespeci thrombot microangiopathi
tma stress still consider unmet need within ahu one
signific commonli cite issu administr burden given
frequenc biweekli soliri dose despit rel rapid infus hour
patient cite hassl schedul visit transport center
case may requir full day traveland addit time requir
facil includ paper-work initi work-up etc
patient dont like frequenc dose receiv infus take almost
entir day pain neck hour travel
center treatment may well involv day beforehand
patient acut attack treat decid
discontinu recov usual he tire go everi week
among unmet need especi treatment ahu prescrib note
patient continu experi on-going hemolysi despit treatment
except per op analysisnewnewnewnewr barclay
soliri attribut issu inabl drug access certain
compartmentswith other suggest issu product
heterolog natur ahu underli caus remain unclear
subset patient howev whole unmet need consid much
less issu dose frequenc see
ahu phase result expect posit
given total data thu far includ notabl disclos detail phase
pnh studi see thought complement relat abstract
 posit data set next leg alexion stori
kol unanim expect ahu phase outcom
expect would posit support registr applic
comfort pnh ahu data like still want
see though
thought pnh data look good want see patient experi
world headach someth make worri
initi adopt ahu like slow prescrib convinc
sustain efficaci abil treat flare-up
kol expect overal result ahu studi posit non-inferior
soliri suggest ahu prescrib like focu two aspect
treatmentwhich like determin uptak first sustain efficacyi
whether suppress activ suffici throughout entir week
durationgiven concern potenti gap would difficult manag given
challeng re-arrest biochem cascad would therefor result poor
clinic outcom issu abil treat acut flare-up given mani
patient present stage
fact non-inferior isnt concern im concern
patient could still sick week dose monitor see theyr
could still sick therapeut level may enough especi
come acute-phas
ou want see pk/pd drug short tail end
right next dose there realli benefitther drug left there
gap issu diseas like ahu take anim studi
healthi volunt studi grain salt
your deal cascad system becom activ
therapi wane run issu sure monitor patient check ldh
level frequent that hassl inconveni concern real
world want comfort therapi level sustain
patient eventu like switch approv
assum prove effect kol anticip becom eventu
standard care see soliri like reserv patient
difficult treat diseas would like benefit frequent dose
think clean non-inferior patient ultim switch year
would reason switch unless want treat patient
activ would small popul
think patient activ would better suit dose
kol opin subcutan formul would even
optim even dose interv frequent weekli despit
concern patient may forgo treatment self-administ
cours better pov patient easier disrupt still
concern patient take drug frank point
scare patient underscor signific take drug
kol also suggest payer would unlik challeng access
approv stress access soliri gener favorablemost
come conclus treatment drug cost-
effect someon admit icu due acute-flare-up
begin difficult get payer board liabil
dont cover dont get patient incur much greater cost
icu admiss dialysi huge cost also neg press
drug approv there right prevent access
initi switch like driven patient
given emphasi option requir less frequent administ agent kol
unanim approvedwa like push patient
awar drug rel high contrast given concern among kol
well like rest commun prescrib like retic use
think mani prescrib still want wait see data prescrib
rare diseas given size studi outcom still
like anecdot evid dont know caus ahu dont know
underli mutat tell may differ respons
see patient respond
concern abil control acut flare-up mani suggest
soliri would like remain primari option patient requir immedi care
icu there greater comfort
initi new patient present icu think your still go see soliri
use least initi year road ye there similar
soliri acut mainten treatment ye youll see start
alexion competit threat consid minim new entrant like
vie nich applic refractory/ intoler
kol also adam competit riskespeci near-termto alexion
minim given substanti inroad compani made ad prescrib
experi comfort critic space kol stress competitor
especi one similar moa antibodi directli target complex
would need demonstr least non-inferior head-to-head studi outright
superior gain signific traction moreov soliri refractory/ intoler
patient remain unmet need spacemak valid clinic focusour kol
stress overal market space rel minor question strategi target
patient even
initi beyond strateg rational howev among
competitor cite potenti interest approach achillion target
factor small molecul inhibitor apelli target pegyl
point alexion pretti much run show take sever year
maker come market
success compet directli soliri think competitor would
show least non-inferior studi superior would take lot realli
wont easi whoever come market first take major market
that alexion one toppl right away alexion grown
big even there differenti like tissu penetr better tough
replac time experi solirisit massiv
competitor find nich breakthrough patient soliri
stop work doesnt work well mayb ahu patient
competitor find nich sure market small
among competitor ive seen like achillion approach theyr target
differ part pathway like use small molecul could offer
altern antibodi develop also like apelli still peptid
circular design novel look altern soliri
hit anoth part path isnt antibodi
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
